Holler Ernst
Department of Haematology/Oncology, University Medical Centre, Regensburg, Germany.
Curr Opin Hematol. 2007 Nov;14(6):625-31. doi: 10.1097/MOH.0b013e3282f08dd9.
The aim of this article is to highlight both experimental and clinical studies contributing to our present understanding of acute graft versus host disease.
New cellular players and new molecules in induction, modulation and treatment of graft versus host disease are reported. The contribution of antigen presenting cells to induction of graft versus host disease and graft versus leukemia effects is well understood in animal models and now needs confirmation in human analyses. Both, regulatory T cells and mesenchymal stem cells are a new hope for prophylaxis and treatment. Receptors of innate immunity, homing molecules and chemokines regulate activation and trafficking of these cellular players and may be used for selective blockade, activation or cell selection.
Better understanding of the early events involved in graft versus host disease should allow risk adapted and more precise early or even preemptive treatment of graft versus host disease.
本文旨在强调有助于我们目前对急性移植物抗宿主病理解的实验性和临床研究。
报道了移植物抗宿主病诱导、调节和治疗中的新细胞参与者和新分子。在动物模型中，抗原呈递细胞对移植物抗宿主病诱导和移植物抗白血病效应的作用已得到充分理解，现在需要在人体分析中得到证实。调节性T细胞和间充质干细胞都是预防和治疗的新希望。固有免疫受体、归巢分子和趋化因子调节这些细胞参与者的激活和转运，可用于选择性阻断、激活或细胞选择。
更好地理解移植物抗宿主病早期事件应有助于对移植物抗宿主病进行风险适应性更强、更精确的早期甚至抢先治疗。
